Understanding The Potential Drug Target UBE2J1 (G51465)

Target Name: UBE2J1

NCBI ID: G51465

UBE2J1

Understanding The Potential Drug Target UBE2J1

UBE2J1 (HSUBC6e), a gene encoding a protein known as UBE2J1 (UBE2J1 gene), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function make it an intriguing target for researchers to study.

The UBE2J1 gene is located on chromosome 1p36 and encodes a protein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract. The protein has a unique structure, with a N-terminal region that is rich in conserved amino acids, a central region that is involved in protein-protein interactions, and a C-terminal region that contains a unique glycophosphorylated site.

The UBE2J1 protein plays a critical role in various physiological processes, including cell signaling, protein-protein interactions, and cell adhesion. It is involved in the regulation of cell proliferation, differentiation, and survival, and its dysfunction has been implicated in various diseases.

One of the most promising aspects of the UBE2J1 protein is its potential as a drug target. The N-terminal region of the protein is rich in conserved amino acids, making it a potential target for small molecules that can modulate its activity. Additionally, the C-terminal region has a unique glycophosphorylated site, which can make it more susceptible to inhibitors that target protein-protein interactions.

Research has shown that UBE2J1 is involved in various signaling pathways, including the TGF-β pathway, which plays a critical role in cancer development. The TGF-β pathway is a well-established target for many anti-cancer drugs, including inhibitors of the hedgehog signaling pathway, which is thought to contribute to the development of many cancers.

In addition to its involvement in the TGF-β pathway, UBE2J1 is also involved in the Wnt signaling pathway, which is involved in the development and maintenance of tissues and organs. The Wnt signaling pathway has been implicated in the development of many neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

UBE2J1 has also been shown to be involved in the intercellular adhesion molecule (ICAM) pathway, which is involved in the regulation of cell-cell interactions and has been implicated in various diseases, including cancer. The ICAM pathway is a potential target for anti- cancer drugs that can inhibit cell-cell interactions.

In conclusion, UBE2J1 is a protein with a unique structure and function that has been identified as a potential drug target and biomarker for various diseases. Its involvement in the TGF-β, Wnt, and ICAM pathways makes it an attractive target for small molecules that can modulate its activity. Further research is needed to fully understand the role of UBE2J1 in disease development and to develop effective treatments.

Protein Name: Ubiquitin Conjugating Enzyme E2 J1

Functions: Catalyzes the covalent attachment of ubiquitin to other proteins. Functions in the selective degradation of misfolded membrane proteins from the endoplasmic reticulum (ERAD) and is essential for cells to recover from ER stress (PubMed:28321712). Plays a role in MAPKAPK2-dependent translational control of TNF-alpha synthesis (PubMed:24020373). Acts also as a platform for perinuclear positioning of the endosomal system by mediating ubiquitination of SQSTM1 through interaction with the E3 ubiquitin-protein ligase RNF26 (PubMed:33472082)

The "UBE2J1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2J1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets